Sarjana Dutt Email & Phone Number

Current responsibilities include-Strategy Planning - Identifying and developing new streams for long term revenue growth and maintaining relationships with customers to achieve repeat referral businessBusiness Development - Initiating and developing relationships with key decision makers in target organizations for business developmentTechnical Responsibilities- Heading Molecular Biology & Cytogenetics DepttLab Management and Operations- Handling routine day to day lab activities – administrative, budgeting, reporting, documentation and training.

Gurugram, Haryana, In

Current responsibilities include-Strategy Planning - Identifying and developing new streams for long term revenue growth and maintaining relationships with customers to achieve repeat referral businessBusiness Development - Initiating and developing relationships with key decision makers in target organizations for business developmentTechnical Responsibilities- Clinical reporting for PCRs, Companion diagnostics assay, Molecular cytogenetics and FISH- Heading the R & D team for development, standardization and validation of new clinically relevant molecular assays in Hematopathology.Lab Management and Cinical Trial Operations- Handling routine day to day lab activities – administrative, budgeting, reporting, documentation and training.People Management/ Training

Gurugram, Haryana, In

Responsibilities included-•Heading the Molecular Diagnostics, R & D and Cytogenetics sections•Clinical reporting for Infectious and Oncology PCRs and FISH•Heading the R & D team for development, standardization and validation of new clinically relevant molecular assays•Strengthening the range of Pharmacogenomic Tests for Drug prognostication•Development of tests for Therapeutic Drug Monitoring

Gurugram, Haryana, In

Launched a series of Pharmacogenetic Tests for Oncology Drug prognostication. Established an Infectious PCR testing section in the laboratory. Successfully guided the laboratory for maintenance of accreditation as per the updated ISO 15189:2007 standards. Applied for CAP assessment in 2009

Given the additional responsibility of managing the QA and QC section of OncQuest towards maintenance of NABL certification (ISO 15189) along with Clinical reporting for Leukemia and Lymphoma samples in the PCR, Flow Cytometry and FISH sections.

Was responsible for establishing and managing the PCR, Flow Cytometry and FISH sections for clinical reporting of Leukemias and Lymphomas. Responsible for identifying and spearheading key research areas in the field of oncology diagnostics directed towards establishment and commercialization of novel molecular assays. Launched the first Drug Resistance Screening Assay for CML patients in India

Was responsible for establishing and managing a Molecular Diagnostics Laboratory started as a collaboration between DRF and RGCI & RC, Delhi; with a primary focus on Clinical reporting for Oncology diagnosis and prognosis. The identification of specific genetic lesions in leukemias by the use of reverse-transcription polymerase chain reaction (RT-PCR) has proven extremely useful for rapid diagnosis and sensitive detection of minimal residual disease (MRD). Our focus of interest included but was not limited to the use of qualitative and quantitative PCR based assays for the diagnosis and MRD detection of genetic lesions and the immunophenotyping of leukemias and lymphomas.

Ghaziabad, Uttar Pradesh, In

Carried out a study on screening and development of Radiolabeled Vasoactive Intestinal Peptide Analogs for Diagnosis and Radiotherapy at Institute of Nuclear Medicine and Allied Sciences (INMAS) as part of a collaboration between DRF and INMAS. A preliminary screening identified Vasoactive Intestinal Peptide as a biomarker of choice as receptors for this peptide are overexpressed on a majority of human epithelial tumors including exocrine, pancreatic, gastric, colonic and small cell lung cancers. Analogs of VIP were designed and screened on human cancer cell lines using Radioligand assays. The analog VP03 was chosen for its high Binding Affinity and further work was directed to develop a 99mTc based VP03 radiopharmaceutical that could be used for the in vivo detection of cancer using Gamma imaging. This study has resulted in a US Patent No: 6,608,174 granted in Aug 2003

Pdf, Molecular Oncology

Ph.D, Molecular Immunology

M.Sc, Biotechnology

B.Sc (Hons), Biochemistry